


Key Components of Our Corporate Strategy

Progress of the Key Components

“Our aspiration is to become a globally-leading medtech company contributing to people’s lives by delivering innovative solutions that benefit patients, healthcare professionals, payors and providers.” This is Olympus’ strategic aspiration under the corporate strategy. As a milestone, we aim to achieve an adjusted operating margin*¹ of over 20% for fiscal year 2023. To achieve this target, we are promoting various initiatives.

*¹ Operating Profit excludes “Other income/expenses.” No adjustments are made for the impact of exchange rate fluctuations; actual exchange rates are used.



- Decided to reorganize Scientific Solutions Business through Company Split and accelerated efforts to implement Company Split. (In August 2022, Olympus decided to transfer all shares of its subsidiary Evident Corporation, which is engaged with the Scientific Solutions Business, to third party. The transfer is scheduled in January 2023.)
- Strengthened measures in the focus areas of GI, Urology, and Respiratory.
 - Continued to expand sales of EVIS X1 advanced endoscopy system through launch execution in current markets and preparation of launch into new markets including, the U.S. and China.
 - Aggressively introduced new products and expanded sales of mainstay products in GI-Endotherapy and achieved positive year-on-year growth for all product categories.
 - Drove double-digit growth in Plasma Resection for BPH & bladder cancer while generating significant incremental revenue and profit through the SOLTIVE SuperPulsed Laser System launch.
 - Ongoing market expansion of EBUS-TBNA portfolio fueled by launch of new EBUS bronchoscope in U.S. and China last year and expanded lung cancer solution with Veran SPIN electromagnetic navigation platform.
- Expanded sales of surgical endoscopy system VISERA ELITE II. Launched infrared (IR) compatible light source in Chinese market in the fiscal year 2022.
- Strengthened the product capabilities of service contract options in each region and developed measures to increase the contract attachment rate through promotions to customers.
- Promoted R&D activities for the realization of the digital endosuite.*²
- Established Olympus Innovation Ventures, a corporate venture capital fund.

*² A solution that could extend the reach of endotherapies while improving the patient experience, using artificial intelligence (AI) and other digital tools and technologies.